Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma | MicrobiomeTrials← Back to trialsNCT07646717
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-02-24Est. Completion: 2027-12-31
Enrollment target: 30 participants Locations- Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Other microbiome trials you might be interested in
Intrahepatic Cholangiocarcinoma (Icc)
This study aims to evaluate whether adding celecoxib to standard therapy can improve clinical outcomes in patients with …
Multiple LocationsEst. completion Dec 31, 2029
Metastatic Colorectal Cancer (Mcrc)Intrahepatic Cholangiocarcinoma (Icc)Intrahepatic Bile Duct CancerColorectal NeoplasmsColorectal Cancer
Cholangiocarcinoma
Bile Duct Neoplasms
Bile Duct Cancer
Adrenocortical Carcinoma (ACC)
Adrenal Cortical Carcinoma
Adrenal Gland Cancer
Adrenal Gland Neoplasms
Adrenal Cortex Neoplasms
Background:
One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body…
Bethesda, United StatesEst. completion Dec 31, 2027